Zobrazeno 1 - 10
of 1 007
pro vyhledávání: '"glp-2"'
Publikováno v:
Nutrition and Dietary Supplements, Vol Volume 16, Pp 165-175 (2024)
Joel Faintuch,1 Andre Dong Won Lee,2 Salomao Faintuch,3 Asher Mishaly,4 Francisco Juarez Almeida Karkow5 1Department of Gastroenterology, Sao Paulo University Medical School, Sao Paulo, SP, Brazil; 2Liver and Digestive Organs Transplantation Service,
Externí odkaz:
https://doaj.org/article/c9c5a675cea6470a92f975e4a8b858c0
Autor:
Engin Yurtcu, Betul Keyif, Gamze Yilmaz, Selcuk Erkilinc, Hatice Akkaya, A. Seval Ozgu-Erdinc
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background This study aimed to evaluate the role of serum Glucagon-Like Peptide-1 (GLP-1), Glucagon-Like Peptide-2 (GLP-2), and Glucose-Dependent Insulinotropic Polypeptide (GIP) levels in relation to obesity and gestational diabetes mellitu
Externí odkaz:
https://doaj.org/article/678903140fd74c868b3f751d3fd77a01
Autor:
Dobromiła Osuch, Piotr Zatyka, Adam Słomczyński, Agata Pawłowska, Michal Rabenda, Piotr Janik, Dominika Opala
Publikováno v:
Quality in Sport, Vol 17 (2024)
Introduction: Inflammatory bowel disease (IBD) is a chronic condition that involves long-term treatment and chronic idiopathic inflammation within the gastrointestinal tract. The predominant forms of IBD are: Crohn's disease and ulcerative colitis.
Externí odkaz:
https://doaj.org/article/8da0db67639f4c0c8ce31f206aa0039d
Autor:
Valentina Marotti, Yining Xu, Cécilia Bohns Michalowski, Wunan Zhang, Inês Domingues, Hafsa Ameraoui, Tom G. Moreels, Pieter Baatsen, Matthias Van Hul, Giulio G. Muccioli, Patrice D. Cani, Mireille Alhouayek, Alessio Malfanti, Ana Beloqui
Publikováno v:
Bioactive Materials, Vol 32, Iss , Pp 206-221 (2024)
Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, v
Externí odkaz:
https://doaj.org/article/3f85c90a219f44b0bab7992bff6c1026
Autor:
Majid Mufaqam Syed-Abdul, Lili Tian, Timothy Samuel, Alex Wong, Young-Kwon Hong, Ralph S. Dacosta, Gary F. Lewis
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 7, Pp 954-964 (2024)
Background and Aims: Secretion and transport of intestinal chylomicrons (CMs) via lymphatics to the blood circulation is stimulated primarily by fat ingestion, whereas several other factors have also been shown to play important roles in regulating C
Externí odkaz:
https://doaj.org/article/ef093c3ea85443759ae55eb04bb6d0ea
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Bone is a highly dynamic organ that changes with the daily circadian rhythm. During the day, bone resorption is suppressed due to eating, while it increases at night. This circadian rhythm of the skeleton is regulated by gut hormones. Until now, gut
Externí odkaz:
https://doaj.org/article/1caa70f22160469584542bd5bf585953
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sol Ramírez-Ochoa, Luis Asdrúval Zepeda-Gutiérrez, Mauricio Alfredo Ambriz-Alarcón, Berenice Vicente-Hernández, Gabino Cervantes-Guevara, Karla D. Castro Campos, Karla Valencia-López, Gabino Cervantes-Pérez, Mariana Ruiz-León, Francisco Javier Hernández-Mora, Tania Elizabeth Cervantes-Nápoles, María Elena Flores-Villavicencio, Sandra O. Sánchez-Sánchez, Enrique Cervantes-Pérez
Publikováno v:
Diagnostics, Vol 14, Iss 19, p 2114 (2024)
Intestinal failure (IF) is a debilitating condition characterized by the insufficient function of the gastrointestinal tract to absorb nutrients and fluids essential for life. This review consolidates recent advancements and challenges in managing IF
Externí odkaz:
https://doaj.org/article/4e7dcfbc557a4563a9b8ee419cc7c9ee
Autor:
Zamara Mariam, Sarfaraz K. Niazi
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 7, Iss 1, Pp n/a-n/a (2024)
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as promising therapeutic options for addressing Type‐2 diabetes, obesity, and related conditions. Among these, semaglutide, tirzepatide, liraglutide etc., a
Externí odkaz:
https://doaj.org/article/6587ac8cd1b24b0db0a4fa0b13a89e71
Autor:
Jolanta Skarbaliene, Jesper Mosolff Mathiesen, Bjarne Due Larsen, Christian Thorkildsen, Yvette Miata Petersen
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-ac
Externí odkaz:
https://doaj.org/article/914d3c0bb5004d14a880381ddc36d5ff